In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

According to Reuters, the grocery retailer notified Express Scripts in September 2022 of its plan to terminate the pharmacy provider agreement for commercial customers because of an “unsustainable” ...

ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January 2023 and in the EU in 2018. Humira's sales are declining due to the ...

Abbvie’s management continues to work through the loss of exclusivity from Humira, switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.” While we acknowledge the potential ...

AbbVie Inc (NYSE:ABBV) delivered full-year adjusted earnings per share of $10.12, exceeding initial guidance by $0.49. Total net revenues were $56.3 billion, surpassing initial guidance by more than ...

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Carrie Strom; Senior Vice President, AbbVie and President, Global Allergan Aesthetics; AbbVie Inc Roopal Thakkar; ...

AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's ...

These strong results demonstrate AbbVie's resilience in navigating the transition away from its former flagship product, as Humira sales decreased by 49% to $1.68 billion in the fourth quarter.

AbbVie demonstrated solid performance in Q4 2024, with its ex-HUMIRA platform contributing significantly to growth. The platform reported an 18% increase in full-year sales, accelerating to 22% in the ...